1-(3-Hydroxypropyl)-1,2,3-triazole → 4-(Indol-5-ylamino)-6-methoxy-7-(3-(1,2,3-triazol-1-yl)propoxy)quinazoline
반응식
[OH:1][C:2]1[CH:11]=[C:10]2[C:5]([C:6]([NH:12][C:13]3[CH:14]=[C:15]4[C:19](=[CH:20][CH:21]=3)[NH:18][CH:17]=[CH:16]4)=[N:7][CH:8]=[N:9]2)=[CH:4][C:3]=1[O:22][CH3:23].[N:24]1([CH2:29][CH2:30][CH2:31]O)[CH:28]=[CH:27][N:26]=[N:25]1>>[NH:18]1[C:19]2[C:15](=[CH:14][C:13]([NH:12][C:6]3[C:5]4[C:10](=[CH:11][C:2]([O:1][CH2:31][CH2:30][CH2:29][N:24]5[CH:28]=[CH:27][N:26]=[N:25]5)=[C:3]([O:22][CH3:23])[CH:4]=4)[N:9]=[CH:8][N:7]=3)=[CH:21][CH:20]=2)[CH:16]=[CH:17]1참가 물질
3
실험 절차
Using an analogous procedure to that described in Example 205, 7-hydroxy-4-(indol-5-ylamino)-6-methoxyquinazoline (98 mg, 0.32 mmol), (prepared as described for the starting material in Example 201), was reacted with 3-(1,2,3-triazol-1-yl)propan-1-ol (61 mg, 0.48 mmol) to give 4-(indol-5-ylamino)-6-methoxy-7-(3-(1,2,3-triazol-1-yl)propoxy)quinazoline (56 mg, 42%).
후처리
- custom(prepared